In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Prothena (PRTA – Research Report), with a price target of $75.00. The company’s shares closed yesterday at $57.69.
According to TipRanks, Fein is an analyst with an average return of -11.0% and a 32.67% success rate. Fein covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Matinas BioPharma, and Wave Life Sciences.
In addition to H.C. Wainwright, Prothena also received a Buy from JMP Securities’s Jason Butler in a report issued today. However, on the same day, RBC Capital downgraded Prothena (NASDAQ: PRTA) to a Hold.
See Insiders’ Hot Stocks on TipRanks >>
PRTA market cap is currently $2.71B and has a P/E ratio of 2,298.41.
Based on the recent corporate insider activity of 63 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PRTA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Prothena Corp. Plc is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories. Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson’s disease. The company was founded in December 1969 and is headquartered in Dublin, Ireland.
Read More on PRTA:
